Alnylam Initiates Phase II Clinical Trial With ALN-TTRsc, A Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) In Development For The Treatment Of TTR-Mediated Amyloidosis (ATTR)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, announced today that it has initiated a pilot
Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi
therapeutic targeting the...